What new gsk patent policy means for the developing world
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Analysts welcome focus on cancer drugs for poorest countries but caution that more work needs to be done. Access through your institution Buy or subscribe This is a preview of subscription
content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 51 print issues and online access $199.00 per year only $3.90 per issue
Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL
ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support Authors * Asher Mullard View author publications You can also search for this
author inPubMed Google Scholar ADDITIONAL INFORMATION Tweet Facebook LinkedIn Weibo RELATED LINKS RELATED LINKS RELATED LINKS IN NATURE RESEARCH The GHIT fund shows its cards 2013-Nov-29
India spurns cancer patents 2013-Aug-13 Straight talk with...Ellen 't Hoen 2010-Dec-06 Drug patent plan gets mixed reviews 2009-Feb-23 RELATED EXTERNAL LINKS RIGHTS AND PERMISSIONS
Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Mullard, A. What new GSK patent policy means for the developing world. _Nature_ (2016).
https://doi.org/10.1038/nature.2016.19695 Download citation * Published: 05 April 2016 * DOI: https://doi.org/10.1038/nature.2016.19695 SHARE THIS ARTICLE Anyone you share the following link
with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt
content-sharing initiative